Tech Company Financing Transactions
Amplo Biotechnology Funding Round
Amplo Biotechnology, based in Pompano Beach, secured investment from National Institutes of Health and NIAMS.
Transaction Overview
Company Name
Announced On
5/29/2023
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
National Institutes of Health (Lead Investor)
NIAMS (Lead Investor)
Proceeds Purpose
This grant will provide funding for the advancement of AMP-201, an AAV-ColQ gene therapy designed to address the severe congenital myasthenic syndrome (CMS) caused by Collagen Q (ColQ) Deficiency.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2637 East Atlantic Blvd 43644
Pompano Beach, FL 33062-4939
USA
Pompano Beach, FL 33062-4939
USA
Phone
Undisclosed
Website
Email Address
Overview
Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo's lead program, AMP-101 (AAV-Dok7), was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Patricio Sepulveda
President
Al Hawkin
Browse more venture capital transactions:
Prev: 5/29/2023: zkMe venture capital transaction
Next: 5/29/2023: Altigreen Propulsion Labs venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs